Boštjan Šeruga

10.2k total citations · 3 hit papers
124 papers, 7.4k citations indexed

About

Boštjan Šeruga is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Boštjan Šeruga has authored 124 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 38 papers in Cancer Research and 34 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Boštjan Šeruga's work include Economic and Financial Impacts of Cancer (20 papers), Health Systems, Economic Evaluations, Quality of Life (19 papers) and Statistical Methods in Clinical Trials (19 papers). Boštjan Šeruga is often cited by papers focused on Economic and Financial Impacts of Cancer (20 papers), Health Systems, Economic Evaluations, Quality of Life (19 papers) and Statistical Methods in Clinical Trials (19 papers). Boštjan Šeruga collaborates with scholars based in Canada, Slovenia and Spain. Boštjan Šeruga's co-authors include Eitan Amir, Ian F. Tannock, Alberto Ocaña, Arnoud J. Templeton, Francisco Vera-Badillo, Mairéad G. McNamara, Jennifer J. Knox, Guru Sonpavde, Priya Aneja and Raya Leibowitz‐Amit and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and PLoS ONE.

In The Last Decade

Boštjan Šeruga

119 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

2014 2.3k citations Arnoud J. Templeton, Mairéad G. McNamara et al. profile →
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

2014 546 citations Arnoud J. Templeton, Olga Ace et al. Cancer Epidemiology Biomarkers & Prevention profile →
Cytokines and their relationship to the symptoms and outcome of cancer

2008 525 citations Boštjan Šeruga, Lori J. Bernstein et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Boštjan Šeruga Canada	34	4.4k	1.8k	1.6k	1.2k	809	124	7.4k
Amanda L. Blackford United States	48	3.6k 0.8×	1.4k 0.7×	1.3k 0.8×	1.7k 1.5×	941 1.2×	227	7.5k
J.W.R. Nortier Netherlands	44	3.5k 0.8×	1.2k 0.7×	1.9k 1.1×	952 0.8×	681 0.8×	157	7.8k
Lee S. Schwartzberg United States	49	6.0k 1.4×	2.3k 1.3×	1.5k 0.9×	1.4k 1.2×	1.7k 2.1×	422	10.2k
Arnoud J. Templeton Switzerland	40	5.6k 1.3×	2.6k 1.4×	1.9k 1.2×	1.1k 1.0×	1.5k 1.8×	152	8.6k
Esther Bastiaannet Netherlands	45	4.5k 1.0×	1.6k 0.9×	1.8k 1.1×	847 0.7×	1.6k 1.9×	263	6.9k
Massimo Di Maïo Italy	50	5.1k 1.2×	3.9k 2.1×	1.4k 0.9×	2.0k 1.7×	1.1k 1.3×	403	9.3k
Paul Sabbatini United States	45	4.0k 0.9×	1.9k 1.0×	658 0.4×	1.8k 1.5×	1.5k 1.8×	182	8.8k
Francisco Vera-Badillo Canada	27	3.4k 0.8×	1.6k 0.9×	1.2k 0.8×	754 0.6×	902 1.1×	76	5.5k
Hyunsoon Cho South Korea	29	2.8k 0.6×	1.6k 0.9×	868 0.5×	1.5k 1.3×	977 1.2×	83	6.8k
James L. Wade United States	45	4.3k 1.0×	2.0k 1.1×	1.3k 0.8×	1.3k 1.1×	796 1.0×	153	7.6k

Countries citing papers authored by Boštjan Šeruga

Since Specialization

Citations

This map shows the geographic impact of Boštjan Šeruga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boštjan Šeruga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boštjan Šeruga more than expected).

Fields of papers citing papers by Boštjan Šeruga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boštjan Šeruga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boštjan Šeruga. The network helps show where Boštjan Šeruga may publish in the future.

Co-authorship network of co-authors of Boštjan Šeruga

This figure shows the co-authorship network connecting the top 25 collaborators of Boštjan Šeruga. A scholar is included among the top collaborators of Boštjan Šeruga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boštjan Šeruga. Boštjan Šeruga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kovač, Milena & Boštjan Šeruga. (2024). Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management. Radiology and Oncology. 58(2). 170–178. 3 indexed citations

Šeruga, Boštjan, et al.. (2024). Aggressive anticancer treatment in the last 2 weeks of life. ESMO Open. 9(3). 102937–102937. 1 indexed citations

Mencinger, Marina, Veronika Kloboves Prevodnik, Srdjan Novaković, & Boštjan Šeruga. (2023). 2337P Feasibility of mutation detection in cytological samples from metastasis in patients with metastatic prostate cancer. Annals of Oncology. 34. S1192–S1192.

Ribnikar, Domen, Ivica Ratoša, Zachary Veitch, et al.. (2023). Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy. Radiology and Oncology. 57(2). 220–228. 1 indexed citations

Tibau, Ariadna, et al.. (2022). Clinical benefit of cancer drugs approved in Switzerland 2010–2019. PLoS ONE. 17(6). e0268545–e0268545. 3 indexed citations

Saleh, Ramy, Nicholas Meti, Domen Ribnikar, et al.. (2020). Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors. Cancer Medicine. 9(21). 7888–7895. 4 indexed citations

Shepshelovich, Daniel, Ariadna Tibau, Hadar Goldvaser, et al.. (2019). Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. Mayo Clinic Proceedings. 94(1). 74–83. 7 indexed citations

Yao, Christie, et al.. (2016). Pretreatment Differences in Intraindividual Variability in Reaction Time between Women Diagnosed with Breast Cancer and Healthy Controls. Journal of the International Neuropsychological Society. 22(5). 530–539. 34 indexed citations

Ocaña, Alberto, Dolores C. Garcı́a-Olmo, Arnoud J. Templeton, et al.. (2015). Circulating DNA and Survival in Solid Tumors. Cancer Epidemiology Biomarkers & Prevention. 25(2). 399–406. 31 indexed citations

10.

Šeruga, Boštjan, Alberto Ocaña, Eitan Amir, & Ian F. Tannock. (2015). Failures in Phase III: Causes and Consequences. Clinical Cancer Research. 21(20). 4552–4560. 61 indexed citations

11.

Al-Mubarak, Mustafa, Francisco Vera-Badillo, Arnoud J. Templeton, et al.. (2015). Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clinical Oncology. 28(5). 283–291. 4 indexed citations

12.

Templeton, Arnoud J., Olga Ace, Mairéad G. McNamara, et al.. (2014). Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiology Biomarkers & Prevention. 23(7). 1204–1212. 546 indexed citations breakdown →

13.

Vera-Badillo, Francisco, Alberto Ocaña, Arnoud J. Templeton, et al.. (2014). Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment. 146(2). 235–244. 57 indexed citations

14.

Salapura, Vladka, et al.. (2013). Osteoblastic bone metastases from renal cell carcinoma. Radiology and Oncology. 48(3). 243–246. 10 indexed citations

15.

Al-Mubarak, Mustafa, Adrian G. Sacher, Alberto Ocaña, et al.. (2013). Fulvestrant for advanced breast cancer: A meta-analysis. Cancer Treatment Reviews. 39(7). 753–758. 21 indexed citations

16.

Amir, Eitan, Alberto Ocaña, Boštjan Šeruga, Orit Freedman, & Mark Clemons. (2010). Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treatment Reviews. 36(5). 410–415. 28 indexed citations

17.

Šeruga, Boštjan & Eitan Amir. (2010). Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Research and Treatment. 122(3). 609–617. 33 indexed citations

18.

Šeruga, Boštjan, et al.. (2009). Global drug development in cancer: a cross-sectional study of clinical trial registries. Annals of Oncology. 21(4). 895–900. 14 indexed citations

19.

Amir, Eitan, et al.. (2009). Amenorrhoea, menopause, and endocrine therapy for breast cancer. BMJ. 339(dec03 2). b4261–b4261. 8 indexed citations

20.

Šeruga, Boštjan, et al.. (2006). Preoperative concomitant chemoradiotherapy in esophageal cancer. Radiology and Oncology. 40(4). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact